ArticleDiabetes care2022
Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.JAMA · 2026Pooled it
- Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry.European heart journal. Quality of care & clinical outcomes · 2026Article
- Trends in Second-Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population-Based Study, 2019-2024.Diabetes, obesity & metabolism · 2026Article
- Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States.Cost effectiveness and resource allocation : C/E · 2026Article
- A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift.Frontiers in pharmacology · 2026Review
- Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.Diabetes, obesity & metabolism · 2025Article
- Improving CKD Screening and Care in Diabetes Using Clinical Decision Support in a Large Health Care System.Kidney360 · 2025Article
- Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Long-term lessons from EMPA-KIDNEY.Nature reviews. Nephrology · 2025Article
- Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence.Pharmacy (Basel, Switzerland) · 2025Review
- Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Safety and efficacy of SGLT2i administration in dilated cardiomyopathy: protocol for a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Article
- Finerenone in diabetic kidney disease: a new frontier for slowing disease progression.Frontiers in medicine · 2025Review
- Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.JAMA network open · 2024Article
- Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.Seminars in nephrology · 2024Review
- International consensus on post-transplantation diabetes mellitus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Cardiovascular-Kidney-Metabolic Health Syndrome: What Does the American Heart Association Framework Mean for Nephrology?Journal of the American Society of Nephrology : JASN · 2024Article
- Unlocking the potential: boosting SGLT2 inhibitor uptake to prevent the cardiorenal consequences of chronic kidney disease.The Lancet regional health. Western Pacific · 2024Article
- Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.EClinicalMedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo assess the prevalence and correlates of prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1-RA) in individuals with type 2 diabetes mellitus (T2DM) with and without chronic kidney disease (CKD). RESEARCH DESIGN AND
methodsThis was a cross-sectional analyses of SGLT2i and GLP1-RA prescriptions from 1 January 2019 to 31 December 2020 in the Veterans Health Administration System. The likelihood of prescriptions was examined by the presence or absence of CKD and by predicted risks of atherosclerotic cardiovascular disease (ASCVD) and end-stage kidney disease (ESKD).
resultsOf 1,197,880 adults with T2DM, SGLT2i and GLP1-RA were prescribed to 11% and 8% of patients overall, and to 12% and 10% of those with concomitant CKD, respectively. In adjusted models, patients with severe albuminuria were less likely to be prescribed SGLT2i or GLP1-RA versus nonalbuminuric patients with CKD, with odds ratios (ORs) of 0.91 (95% CI 0.89, 0.93) and 0.97 (0.94, 1.00), respectively. Patients with a 10-year ASCVD risk >20% (vs. <5%), had lower odds of SGLT2i use (OR 0.66 [0.61, 0.71]) and GLP1-RA prescription (OR 0.55 [0.52, 0.59]). A 5-year ESKD risk >5%, compared with <1%, was associated with lower likelihood of SGLT2i prescription (OR 0.63 [0.59, 0.67]) but higher likelihood of GLP1-RA prescription (OR 1.53 [1.46, 1.61]).
conclusionsAmong a large cohort of patients with T2DM, prescription of SGLT2i and GLP1-RA was low in those with CKD. We observed a "risk-treatment paradox," whereby patients with higher risk of adverse outcomes were less likely to receive these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.